Inhibitory effect of minocycline on amyloid β fibril formation and human microglial activation
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Minocycline, a derivative of the antibiotic tetracycline, displays neuroprotective properties in various models of neurodegenerative diseases and is now used in clinical trials, because of its relative safety and tolerability. Minocycline passes the blood‐brain barrier and is presumed to inhibit microglial activation. In Alzheimer's disease brain, a number of proteins, including serum amyloid P component (SAP) and complement factors such as C1q, accumulate in amyloid β (Aβ) plaques. In a previous study, SAP and C1q were found to be required for clustering of activated microglia in Aβ plaques. Furthermore, SAP and C1q enhanced Aβ fibril formation and Aβ mediated cytokine release by human microglia in vitro. In the present study, we report that tetracycline and minocycline dose‐dependently reduce TNF‐α and IL‐6 release by adult human microglia upon stimulation with a combination of Aβ, SAP, and C1q. In addition, minocycline and to a lesser extent tetracycline inhibit fibril formation of Aβ as determined in a thioflavin‐S‐based fluorescence test. This inhibitory effect was observed with Aβ alone as well as with Aβ in combination with SAP and C1q. Our data suggest that minocycline and tetracycline at tolerable doses can inhibit human microglial activation. This activity in part is exerted by inhibition of (SAP and C1q enhanced) Aβ fibril formation. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 2×
“pound were reported in models of Parkinson’s disease (Du et al., 2001; Wu et al., 2002), Huntington’s disease (Chen et al.”
BackgroundMethodIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“…activation of microglia is a relatively early pathologic event in the process of Alzheimer’s disease, since the presence of MHC class II-positive microglia precedes the process of neuropil destruction in AD brain (Sasaki et al., 1997; Arends et al., 2000; Cagnin et al., 2001; Vehmas et al., 2003).”
BackgroundTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 3×
“Several mechanisms may contribute to neuroprotective activities of minocycline such as inhibition of caspase 1 and 3 expression, reduction in generation of inducible nitric oxide synthase (iNOS) and COX-2, and inhibition of p38 MAPK (Yrjanheikki et al., 1998; Yrjanheikki et al., 1999; Chen et al., 2000; Tikka et al.,…”
BackgroundTikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · cited 4×
“A direct inhibitory effect of minocycline on proliferation and activation of rodent microglial cells through inhibition of p38 mitogen-activated protein kinase (p38 MAPK) is suggested, which, in turn, can prevent neurotoxicity (Tikka et al., 2001).”
BackgroundInfluentialLedeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., & Watkins, L. R. (2005) · Pain · doi:10.1016/j.pain.2005.02.009 · Cited by 677
Blasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374 · cited 2×
“ciated with clusters of activated microglia in AD affected brain areas (Sasaki et al., 1997; Veerhuis et al., 2003; Blasko et al., 2004; Veerhuis et al., 2004).”
BackgroundSelf-citationImmune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease
Vehmas, A. K., Kawas, C. H., Stewart, W. F., & Troncoso, J. C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00090-8 · Cited by 230 · cited 2×
“…activation of microglia is a relatively early pathologic event in the process of Alzheimer’s disease, since the presence of MHC class II-positive microglia precedes the process of neuropil destruction in AD brain (Sasaki et al., 1997; Arends et al., 2000; Cagnin et al., 2001; Vehmas et al., 2003).”
BackgroundClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157 · cited 3×
“Intravenous administration of minocycline of 25 mg/kg was reported to be safe and did not alter the physiological parameters of the experimental animals (Colovic and Caccia, 2003; Xu et al., 2004; Blum et al., 2004).”
BackgroundMicroglia, amyloid and dementia in Alzheimer disease
Arends, Y. M., Duyckaerts, C., Rozemuller, J. M., Eikelenboom, P., & Hauw, J.-J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00094-4 · Cited by 139
Self-citationMicroglial activation in early stages of amyloid β protein deposition
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997) · Acta Neuropathologica · doi:10.1007/s004010050713 · Cited by 132 · cited 2×
“Deposition of Ab is considered a neuropathological hallmark of AD and is associated with clusters of activated microglia in AD affected brain areas (Sasaki et al., 1997; Veerhuis et al., 2003; Blasko et al., 2004; Veerhuis et al., 2004).”
Background
Cited by
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
“Minocycline dose dependently reduced tumor necrosis factor-α and IL-6 release by microglia.(90) One last general remark: weight gain is a greater problem for young patients experiencing first-episode psychosis.”
BackgroundThe significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262
Self-citationHoward, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110
“Minocycline, a secondgeneration tetracycline compound, reverts several FXS phenotypes [24], possibly by altered Ab fibril formation [73] or Abinduced neuronal death and glial activation [74].”
BackgroundAnti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
“A one in six series of sections was used for immunohistochemistry with an antibody directed against glial fibrillary acidic protein (GFAP) (DAKO Ltd.) according to a standard protocol (Pontikis et al., 2005).”
BackgroundMethodThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration
van Dijk, G., van Heijningen, S., Reijne, A. C., Nyakas, C., van der Zee, E. A., & Eisel, U. L. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00173 · Cited by 75
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
“Considering the drug anti-Aβ activity, in vitro study of Familian and coworkers demonstrated that minocycline dose-dependently inhibit Aβ1-42 fibril formation in cell culture of adult microglia cells isolated from brains of patients with AD post-mortem (the effect was associated with inhibition of human microglial act…”
Result
Metadata
- Authors
- Familian, A., Boshuizen, R. S., Eikelenboom, P., & Veerhuis, R.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2005-10-11
- Volume
- 53
- Issue
- 3
- Pages
- 233-240
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2102747732
- Cited by
- 85
- References
- 10
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.